PSC-PEG Peptide Chelator for Targeted Alpha Radionuclide Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current peptide receptor radionuclide therapies for neuroendocrine neoplasms, particularly those targeting somatostatin receptor subtype 2 (SSTR2), show limited therapeutic benefit with beta-particle emitters like 177Lu-DOTATATE, and there is a need for more effective radiation delivery to tumors while minimizing exposure to other organs.
Innovation Solution
Development of a new chelator composition, 1,4,7,10-tetraazacyclododecane-7-acetamide-1,4,10-triacetic acid (PSC), with polyethylene glycol (PEG) linkers, to create conjugates that enhance the binding and internalization of alpha-particle emitters like Pb-212 for targeted therapy and imaging, optimizing tumor targeting and biodistribution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If beta-particle emitters like 177Lu-DOTATATE are used for PRRT, then the therapy is FDA-approved and shows some therapeutic benefit, but the response is limited to partial response and complete responses are rarely reported
Solution Approach 1:
The patent changes the radionuclide parameter from beta-particle emitters (177Lu) to alpha-particle emitters (212Pb), which fundamentally alters the radiation delivery mechanism. Alpha particles provide higher linear energy transfer (LET) and relative biological effectiveness (RBE), enabling complete tumor responses that were rarely achieved with beta-particle therapy
Solution Approach 2:
The patent creates a composite structure by conjugating the peptide targeting molecule (DOTATOC) with a new chelator (PSC) that specifically binds alpha-particle emitting radionuclides. This composite radiopharmaceutical combines the tumor-targeting capability of the peptide with the high-LET radiation of alpha emitters, achieving both selective delivery and enhanced therapeutic effect
2Power
If alpha-particle emitters like 212Pb are used, then significantly higher radiation doses and RBE are delivered to tumors, but the challenge is to optimize delivery to minimize exposure to other organs
Solution Approach 1:
The patent optimizes the local properties of the radiopharmaceutical by modifying the chelator structure (PSC) and its linker to the peptide. This ensures stable binding of the alpha-emitting radionuclide specifically at the tumor target site, maintaining high radiation dose delivery to tumors while minimizing off-target exposure through improved selectivity and stability
Solution Approach 2:
The patent uses the PSC chelator as an intermediary between the alpha-particle emitting radionuclide (212Pb) and the tumor-targeting peptide (DOTATOC). This intermediary ensures stable radionuclide binding, prevents premature dissociation and off-target exposure, while maintaining the peptide's ability to selectively bind SSTR2 receptors on tumor cells
3Productivity
If the chelator structure is modified with PSC and PEG linkers, then radiolabeling efficiency and cellular uptake are improved, but the device complexity increases
Solution Approach 1:
The patent segments the chelator structure into distinct functional modules: the PSC chelating core for radionuclide binding, and separate PEG linker segments for controlling spacing and stability. This modular design improves radiolabeling efficiency while making the complex structure more manageable and potentially easier to synthesize through standardized modular assembly
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PSC-PEG-conjugated peptides demonstrate improved radiolabeling efficiency, cellular uptake, and biodistribution, providing higher radiation doses specifically to tumors with reduced exposure to kidneys, thus enhancing therapeutic outcomes for neuroendocrine tumors and other SSTR2-expressing cancers.
Implementation Method 1
Development of a new chelator composition, 1,4,7,10-tetraazacyclododecane-7-acetamide-1,4,10-triacetic acid (PSC), with polyethylene glycol (PEG) linkers, to create conjugates that enhance the binding and internalization of alpha-particle emitters like Pb-212
Implementation Method 2
Alpha-particle emitters are alternatives to the conventional beta-particle emitters bringing significantly higher radiation doses (up to a few hundred fold) in cells and tumor metastases from decays
Implementation Method 3
Lead-212 (212Pb) is an attractive alpha-particle emitter that has a favorable half-life (10.64 h) for clinical application
Implementation Method 4
The structure was further optimized with the additions of polyethylene glycol (PEG) linkers between the chelator and TOC
Implementation Method 5
The majority (>80%) of NENs express somatostatin receptors (3), and among them, somatostatin receptor subtype 2 (SSTR2) is a well-known target for a specific therapy called peptide receptor radionuclide therapy (PRRT)
Data Source
AI summary
The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I wherein T is a SST2R targeting ligand, L is a linker, and X is a chelator, for the therapeutic treatment of cancer, and methods of use thereof.